VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings validating its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. The in vivo study demonstrated significant tumor regression in a breast cancer model following a single 3 mg/kg dose, with no observed decrease in body weight. The results also showed that both BiTAC-ADC components were required to produce the intended tumor-specific response.
Additional in vitro studies demonstrated the platform’s ability to distinguish cancer cells from healthy cells, prevent the release of active toxins outside the tumor, and target multiple cancer cell lines. The findings support the potential of BiTAC-ADCs to deliver efficacy comparable to conventional antibody-drug conjugates while offering a differentiated safety profile designed to reduce systemic toxicity.
This news matters because it represents a significant step forward in the development of next-generation cancer therapies. The ability to selectively target cancer cells while sparing healthy tissue could address one of the major limitations of current treatments: systemic toxicity. If BiTAC-ADCs can achieve similar efficacy to conventional ADCs with fewer side effects, they could become a preferred option for patients and clinicians.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.
To view the full press release, visit https://ibn.fm/cs8SW. The latest news and updates relating to VRXA are available in the company’s newsroom at http://ibn.fm/VRXA.
For more information about VERAXA Biotech, visit VERAXA Biotech (NASDAQ: VRXA). The announcement was covered by BillionDollarClub, a specialized communications platform focused on the biggest and brightest companies covered by IBN, which is part of the Dynamic Brand Portfolio at IBN. The platform delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
Please see full terms of use and disclaimers on the BillionDollarClub website applicable to all content provided by BDC, wherever published or re-published: https://www.BillionDollarClub.com/Disclaimer.
